Drug Profile
Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals
Alternative Names: BCMA GoCAR-NK - Bellicum Pharmaceuticals; BPX 401; BPX 602; BPX-802; BPZ-2003; CaspaCIDe-enabled CD19 CAR; CaspaCIDe® T Cell immunotherapies - Bellicum Pharmaceuticals; Chemical Induction of Dimerization enabled cellular immunotherapies - Bellicum Pharmaceuticals; CIDeCar#1; DeCIDe® based immunotherapies - Bellicum pharmaceuticals; DS GoCAR-T cells - Bellicum Pharmaceuticals; Dual-Switch CAR-T Cells; Dual-switch GoCAR-T cells - Bellicum Pharmaceuticals; GoCAR-T based immunotherapies - Bellicum PharmaceuticalsLatest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator Bellicum Pharmaceuticals
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Haematological malignancies; Solid tumours
Most Recent Events
- 05 Dec 2020 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)
- 31 Oct 2020 Suspended - Preclinical for Haematological malignancies in USA (IV)
- 31 Oct 2020 Suspended - Preclinical for Solid tumours in USA (IV)